KOL Identification Framework for Early-Stage Biotech

Most early-stage biotech teams over-index on famous names and under-index on active signal density. The result is delayed engagement and weaker trial support.

Start with three filters: publication velocity in your target mechanism, clinical trial investigator overlap, and recent speaking activity in your indication.

Then score experts by relevance and accessibility. Relevance protects strategic alignment; accessibility protects timeline execution.

Teams that apply this structure reduce KOL shortlisting cycles and improve first-contact quality. Request a Meddash brief to receive a therapeutic-area specific KOL map.